<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04954846</url>
  </required_header>
  <id_info>
    <org_study_id>PRISE</org_study_id>
    <nct_id>NCT04954846</nct_id>
  </id_info>
  <brief_title>A Randomized Double Blinded Placebo Controlled Study on the Effects of Dietary Supplementation With a Probiotic on Stroke Patients</brief_title>
  <acronym>PRISE</acronym>
  <official_title>Auswirkungen Eines Probiotischen Nahrungsergänzungsmittels Auf Das Darmmikrobiom Von Schlaganfallpatienten (PRISE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine the effects of an intervention using a commercially&#xD;
      available probiotic in a cohort of acute stroke patients. In order to determine this, a&#xD;
      double blinded, randomised and placebo-controlled study design was chosen.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients are recruited from the Stroke Unit of the Ludwig Maximilians University Munich&#xD;
      within seven days of stroke onset. Recruited patients are then randomly assigned to either&#xD;
      the Control or Treatment group and subsequently take the commercially available probiotic, or&#xD;
      the placebo, twice a day for 3 months. At this point, study participants present themselves&#xD;
      for routine clinical examination at the outpatient clinic of the Institute for Stroke and&#xD;
      Dementia Research (ISD). During these examinations, blood and stool samples are collected for&#xD;
      metabolomic and metagenomic analysis. Additionally, questionnaires concerning cognitive&#xD;
      function (MOCA), depression (BDI) and general gastrointestinal status (GSRS-IBS) are&#xD;
      completed.&#xD;
&#xD;
      Clinical data from both acute admission and three month follow-up are also collected for the&#xD;
      purposes of this study.&#xD;
&#xD;
      Furthermore, members of the same household as the study participants are asked to donate a&#xD;
      stool sample. These samples will be used to create a reference cohort for a paired matching&#xD;
      approach with the Treatment and Control groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 18, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alpha diversity, determined via Shannon index</measure>
    <time_frame>3 Months after stroke onset/Begin of diet supplementation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Alpha diversity, determined via phylogenetic diversity index</measure>
    <time_frame>3 Months after stroke onset/Begin of diet supplementation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Montreal Cognitive Assessment (MOCA)</measure>
    <time_frame>3 Months after stroke onset/Begin of diet supplementation</time_frame>
    <description>Range of achievable values is 0 - 31, low values are associated with impaired cognitive function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Becks Depression Inventory (BDI)</measure>
    <time_frame>3 Months after stroke onset/Begin of diet supplementation</time_frame>
    <description>Range of achievable values is 0 - 63, high values are associated with mild (12-19), moderate (20-26) and severe (30-63) depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Institute of Health Stroke Scale (NIHSS)</measure>
    <time_frame>3 Months after stroke onset/Begin of diet supplementation</time_frame>
    <description>Range of achievable values is 0 - 42, high values are associated with more advanced impairment due to stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal Symptom Rating Scale for Irritable Bowel Syndrom (GSRS-IBS)</measure>
    <time_frame>3 Months after stroke onset/Begin of diet supplementation</time_frame>
    <description>Range of achievable values is 13 - 91, high values are associated with more pronounced gastrointestinal symptoms (i.e. pain, diarrhea, discomfort)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale (mRS)</measure>
    <time_frame>3 Months after stroke onset/Begin of diet supplementation</time_frame>
    <description>Range of achievable values is 0 - 5, high values are associated with loss of mobility and autonomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beta diversity, determined via Bray-Curtis dissimilarity</measure>
    <time_frame>3 Months after stroke onset/Begin of diet supplementation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beta diversity, determined via UniFrac</measure>
    <time_frame>3 Months after stroke onset/Begin of diet supplementation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">157</enrollment>
  <condition>Stroke, Ischemic</condition>
  <condition>Dysbiosis</condition>
  <arm_group>
    <arm_group_label>OMNi-BiOTiC SR-9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment is taken twice a day for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo is taken twice a day for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>OMNi-BiOTiC SR-9</intervention_name>
    <description>The Probiotic contains the following ingredients:&#xD;
Maize Starch, Maltodextrin, Inulin, Potassium Chloride, Hydrolysed rice protein, Magnesium Sulphate, Fructooligosaccharides, Amylase, Manganese Sulphate&#xD;
Additionally, the following bacterial strains are included:&#xD;
Lactobacillus Casei W56, Lactobacillus Acidophilus W22, Lactobacillus Paracasei W20, Bifidobacterium lactis W51, Lactobacillus salivarius W24, Lactococcus lactis W19, Bifidobacterium lactis W52, Lactobacillus plantarum, Bifidobacterium bifidum W23</description>
    <arm_group_label>OMNi-BiOTiC SR-9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The Placebo contains no bacterial strains, only the prebiotic ingredients found in OMNi-BiOTiC SR-9.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of ischemic stroke with onset in past 7 days&#xD;
&#xD;
          -  Treatment received in the Stroke Unit of the LMU University Hospital, location&#xD;
             Großhadern&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic immunological disease&#xD;
&#xD;
          -  Severe gastrointestinal disease&#xD;
&#xD;
          -  Colectomy&#xD;
&#xD;
          -  Artificial intestinal outlet (ostomy)&#xD;
&#xD;
          -  Liver cirrhosis, pancreatitis, gastritis, cholecystitis (or other acute&#xD;
             gastrointestinal diseases)&#xD;
&#xD;
          -  Chronic alcohol abuse&#xD;
&#xD;
          -  Terminal prognosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Arthur Liesz, Prof. Dr.</last_name>
    <phone>089 4400 46110</phone>
    <email>Arthur.Liesz@med.uni-muenchen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Philip Melton</last_name>
    <phone>089 4400 46333</phone>
    <phone_ext>+49</phone_ext>
    <email>philip.melton@med.uni-muenchen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ludwig Maximilian University Munich, University Hospital, Site Großhadern</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arthur Liesz, Prof. Dr.</last_name>
      <phone>089 4400 46110</phone>
      <email>arthur.liesz@med.uni-muenchen.de</email>
    </contact>
    <contact_backup>
      <last_name>Philip Melton</last_name>
      <phone>089 4400 46333</phone>
      <email>philip.melton@med.uni-muenchen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Arthur Liesz, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 18, 2021</study_first_submitted>
  <study_first_submitted_qc>June 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2021</study_first_posted>
  <last_update_submitted>July 7, 2021</last_update_submitted>
  <last_update_submitted_qc>July 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ludwig-Maximilians - University of Munich</investigator_affiliation>
    <investigator_full_name>Prof. Dr. med. Arthur Liesz</investigator_full_name>
    <investigator_title>Professor Dr. med. Arthur Liesz</investigator_title>
  </responsible_party>
  <keyword>Gut-Brain Axis</keyword>
  <keyword>Probiotics</keyword>
  <keyword>Food supplements</keyword>
  <keyword>Microbiome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Dysbiosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

